57184-50-6

Usage

Uses

Used in Pharmaceutical Industry:
Piperazine, 1-(2,2-dimethylpropyl)(9CI) is used as an active pharmaceutical ingredient for the development of drugs targeting specific medical conditions. Its unique structure and properties allow it to interact with biological systems, making it a valuable component in the creation of therapeutic agents.
Used in Pesticide Industry:
In the pesticide industry, Piperazine, 1-(2,2-dimethylpropyl)(9CI) is utilized as a key component in the formulation of various pest control products. Its chemical properties enable it to effectively target and control pests, contributing to improved crop protection and yield.
Used in Surfactant Industry:
Piperazine, 1-(2,2-dimethylpropyl)(9CI) is employed as a surfactant in various applications, such as detergents, cleaners, and personal care products. Its ability to reduce surface tension and form micelles makes it an effective ingredient for enhancing the performance of these products.

InChI:InChI=1/C9H20N2/c1-9(2,3)8-11-6-4-10-5-7-11/h10H,4-8H2,1-3H3

Upstream product

• 630-19-3 pivalaldehyde 

Downstream Products

• 1374567-04-0 C₂₆H₃₂ClN₅O₂ 
• 69628-22-4 11-{[4-(2,2-dimethyl-propyl)-piperazin-1-yl]-acetyl}-5,11-dihydro-benzo[e]pyrido[3,2-b][1,4]diazepin-6-one 

Relevant academic research and scientific papers

Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties

Based on the previously reported clinical candidate, AMG 517 (compound 1), a series of related piperazinylpyrimidine analogues were synthesized and evaluated as antagonists of the vanilloid 1 receptor (VR1 or TRPV1). Optimization of in vitro potency and physicochemical and pharmacokinetic properties led to the discovery of (R)-N-(4-(6-(4-(1-(4-fluorophenyl)ethyl) piperazin-1-yl)pyrimidin-4-yloxy)benzo[d]-thiazol-2-yl)acetamide (16p), a potent TRPV1 antagonist [rTRPV1(CAP) IC50 = 3.7 nM] with excellent aqueous solubility (≥200 μg/mL in 0.01 N HCl) and a reduced half-life (rat t 1/2 = 3.8 h, dog t1/2 = 2.7 h, monkey t1/2 = 3.2 h) as compared to AMG 517. In addition, compound 16p was shown to be efficacious at blocking a TRPV1-mediated physiological response in vivo (ED 50 = 1.9 mg/kg, p.o. in the capsaicin-induced flinch model in rats) and was also effective at reducing thermal hyperalgesia induced by complete Freund's adjuvant in rats (MED = 1 mg/kg, p.o). Based on its improved overall profile, compound 16p (AMG 628) was selected as a second-generation candidate for further evaluation in human clinical trials as a potential new treatment for chronic pain.